Luis Chiva

Summary

Country: Spain

Publications

  1. doi request reprint What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
    Luis Chiva
    Department of Gyecologic Oncology, MD Anderson Cancer Center, Madrid, Spain
    Ann Surg Oncol 23:1666-73. 2016
  2. doi request reprint A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
    Luis M Chiva
    MD Anderson Cancer Center Madrid, Spain Electronic address
    Gynecol Oncol 136:130-5. 2015
  3. pmc Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer
    Lorena Alonso-Alconada
    Translational Medical Oncology Health Research Institute of Santiago IDIS, SERGAS, Trav, Choupana s n 15706, Santiago de Compostela, Spain
    Mol Cancer 13:223. 2014
  4. doi request reprint Surgical treatment of recurrent cervical cancer: state of the art and new achievements
    Luis M Chiva
    Department of Gynecologic Oncology, M D Anderson International Espana, Madrid, Spain
    Gynecol Oncol 110:S60-6. 2008
  5. doi request reprint Sparing fertility in young patients with endometrial cancer
    Luis Chiva
    Department of Gynecologic Oncology, MD Anderson International España, Madrid, Spain
    Gynecol Oncol 111:S101-4. 2008
  6. doi request reprint Ileal orthotopic neobladder after pelvic exenteration for cervical cancer
    Luis M Chiva
    Department of Gynecologic Oncology, M D Anderson International Espana, Madrid, Spain
    Gynecol Oncol 113:47-51. 2009
  7. doi request reprint Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
    Alba Mota
    Departamento de Bioquimica, Universidad Autonoma de Madrid UAM, Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, IdiPAZ, Madrid, Spain
    Mod Pathol 30:134-145. 2017
  8. doi request reprint First-line and maintenance therapy for ovarian cancer: current status and future directions
    Antonio González-Martín
    Medical Oncology Department, MD Anderson Cancer Center, C Arturo Soria 270, 28033, Madrid, Spain
    Drugs 74:879-89. 2014
  9. doi request reprint Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting
    Antonio González-Martín
    Medical Oncology Department, Centro Oncológico MD Anderson International España, Madrid, Spain
    Clin Transl Oncol 12:418-30. 2010
  10. doi request reprint Bevacizumab as front-line treatment for newly diagnosed epithelial cancer
    Antonio Gonzalez Martin
    Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
    Expert Rev Anticancer Ther 13:123-9. 2013

Collaborators

  • Alejandro Rojo
  • Antonio Gil-Moreno
  • Xavier Matias-Guiu
  • Antonio Gonzalez Martin
  • Antonio Gonzalez
  • Angel Garcia
  • Antonio González-Martín
  • Alba Mota
  • Gema Moreno-Bueno
  • Pablo García-Sanz
  • Alejandro Rojo-Sebastián
  • Eva Colas
  • Rafael Lopez-Lopez
  • Jaume Reventos
  • Miguel Abal
  • Lorena Alonso-Alconada
  • Sonia Gatius
  • Irene Campoy
  • Sonsoles Alonso
  • Patrycja Ziober-Malinowska
  • Marcin Bobiński
  • Xavier Gonzalez-Tallada
  • Berta Díaz-Feijoo
  • August Vidal
  • Juan F Garcia
  • Juan Carlos Triviño
  • Angel Martinez-Ramirez
  • Frederic Amant
  • Camilla Krakstad
  • Juan Cueva
  • Maite Cusidó
  • Raul Marquez
  • Kadri Madissoo
  • Jone Trovik
  • Laura Muinelo-Romay
  • Javier Mariscal
  • Andrea Romano
  • Josep Castellvi
  • John A Green
  • María Vieito
  • Antonio Diaz-Lopez
  • Amparo Cano
  • Hans W Nijman
  • Elisabeth Wik
  • Dharani Hapangama
  • Lieve Coenegrachts
  • Tjalling Bosse
  • Raquel Bratos
  • Helga B Salvesen
  • Eugenia Ortega
  • Luisa Sanchez-Lorenzo
  • Xavier Dolcet
  • Gemma Toledo

Detail Information

Publications11

  1. doi request reprint What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
    Luis Chiva
    Department of Gyecologic Oncology, MD Anderson Cancer Center, Madrid, Spain
    Ann Surg Oncol 23:1666-73. 2016
    ....
  2. doi request reprint A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
    Luis M Chiva
    MD Anderson Cancer Center Madrid, Spain Electronic address
    Gynecol Oncol 136:130-5. 2015
    ..Our objective was to review the published experiences of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer with a focus on survival outcomes...
  3. pmc Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer
    Lorena Alonso-Alconada
    Translational Medical Oncology Health Research Institute of Santiago IDIS, SERGAS, Trav, Choupana s n 15706, Santiago de Compostela, Spain
    Mol Cancer 13:223. 2014
    ..In the framework of the European Network for Individualized Treatment in EC (ENITEC), we investigated the presence and phenotypic features of Circulating Tumor Cells (CTC) in high-risk EC patients...
  4. doi request reprint Surgical treatment of recurrent cervical cancer: state of the art and new achievements
    Luis M Chiva
    Department of Gynecologic Oncology, M D Anderson International Espana, Madrid, Spain
    Gynecol Oncol 110:S60-6. 2008
    ..Each should undergo a comprehensive evaluation to make sure there is no evidence of unresectable or metastatic disease that would make her an unsuitable candidate for exenteration...
  5. doi request reprint Sparing fertility in young patients with endometrial cancer
    Luis Chiva
    Department of Gynecologic Oncology, MD Anderson International España, Madrid, Spain
    Gynecol Oncol 111:S101-4. 2008
    ..However, consideration should be taken regarding the potential adverse outcomes that have been recently published in the literature...
  6. doi request reprint Ileal orthotopic neobladder after pelvic exenteration for cervical cancer
    Luis M Chiva
    Department of Gynecologic Oncology, M D Anderson International Espana, Madrid, Spain
    Gynecol Oncol 113:47-51. 2009
    ....
  7. doi request reprint Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
    Alba Mota
    Departamento de Bioquimica, Universidad Autonoma de Madrid UAM, Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, IdiPAZ, Madrid, Spain
    Mod Pathol 30:134-145. 2017
    ..Notably, the genetic analysis of uterine aspirates captures this heterogeneity, solving the potential problem of incomplete genetic characterization when a single tumor biopsy is analyzed...
  8. doi request reprint First-line and maintenance therapy for ovarian cancer: current status and future directions
    Antonio González-Martín
    Medical Oncology Department, MD Anderson Cancer Center, C Arturo Soria 270, 28033, Madrid, Spain
    Drugs 74:879-89. 2014
    ....
  9. doi request reprint Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting
    Antonio González-Martín
    Medical Oncology Department, Centro Oncológico MD Anderson International España, Madrid, Spain
    Clin Transl Oncol 12:418-30. 2010
    ..For this reason, there is still a need for new treatments and strategies in the first-line setting...
  10. doi request reprint Bevacizumab as front-line treatment for newly diagnosed epithelial cancer
    Antonio Gonzalez Martin
    Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
    Expert Rev Anticancer Ther 13:123-9. 2013
    ....
  11. pmc Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
    Alba Mota
    Departamento de Bioquimica, Universidad Autonoma de Madrid UAM, Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, IdiPAZ, Madrid, Spain
    BMC Cancer 15:940. 2015
    ..Different studies show that this kind of tumors may have a worse prognosis than other TP53 mutated HGSC...